Pathway enrichment analysis revealed upregulation in EMT, angiogenesis and KRAS signaling, and downregulation in adipogenesis and fatty acid metabolism in both ccRCC and non-ccRCC tumors with chr7 gain (Figure S6G). The gene discussed is KRAS; the disease is nonpapillary renal cell carcinoma.